A Phase 1 Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors or Lymphoma With Homozygous Deletion of MTAP
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2018
At a glance
- Drugs AG-270 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Agios Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 19 Mar 2018 According to an Agios Pharmaceuticals media release, the first patient from this trial has been dosed.
- 28 Feb 2018 Status changed from not yet recruiting to recruiting.